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Background: Sleep disturbances are a common co-occurring disturbance in patients with major 
depressive disorders (MDDs) and accordingly deserve particular attention. Using a random-
ized design, we investigated the effects of three different adjuvant interventions on sleep and 
depression among patients with MDD: a sleep hygiene program (SHP), lorazepam (LOR), and 
their combination (SHP–LOR).
Methods: A total of 120 outpatients with diagnosed MDD (mean age: 48.25 years; 56.7% 
females) and treated with a standard SSRI (citalopram at 20–40 mg at therapeutic level) were 
randomly assigned to one of the following three conditions: SHP (n=40), LOR (1 mg/d; n=40), 
SHP–LOR (1 mg/d; n=40). At the beginning and at the end of the study 8 weeks later, patients 
completed two questionnaires, the Pittsburgh Sleep Quality Index to assess sleep and the Beck 
Depression Inventory to assess symptoms of depression.
Results: Sleep disturbances decreased over time and in all groups. No group differences or 
interactions were observed. Symptoms of depression decreased over time and in all three 
groups. Reduction in symptoms of depression was greatest in the SHP–LOR group and lowest 
in the LOR group.
Conclusion: The pattern of results suggests that all three adjuvant treatments improved 
symptoms of sleep disturbances and depression, with greater benefits for the SHP–LOR for 
symptoms of depression, but not for sleep. Nevertheless, risks and benefits of benzodiazepine 
prescriptions should be taken into account.
Keywords: sleep hygiene, psychoeducation, pharmacotherapy, lorazepam, sleep disturbances, 
depression
Introduction
Restoring sleep is associated with a broad variety of physical,1 emotional,2,3 cognitive,4,5 
and social benefits.6 Poor and nonrestoring sleep, in contrast, leads to impairments on 
physiological, emotional, cognitive, and social levels. In other words, poor sleep is 
associated with impaired daily functioning. This observation holds particularly true 
for people with mental disorders; sleep disturbances are nearly universal features 
of psychiatric disorders, especially mood disorders. Indeed, research investigating 
associations between sleep and affective illness has largely focused on depression 
and major depressive disorder (MDD).7–10
In this regard, epidemiological data indicate that people with psychiatric disorders 
account for 30%–40% of those in the community reporting symptoms of insomnia.11 
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Of those individuals with insomnia, 40%–60% display 
features of depression. Likewise, disturbances in sleep and 
wakefulness, such as insomnia, excessive sleepiness, and 
fatigue, are experienced by most individuals suffering from 
depression, and sleep disorder is among the most prevalent 
symptoms of depression, with rates of ~80%.12,13 As regards 
the direction of influence (whether sleep disturbances lead 
to depressive symptoms, or depressive symptoms lead to 
sleep disturbances), there is growing evidence that sleep 
disturbances are at the beginning of increasing symptoms 
of depression. In their meta-analysis, Lovato and Gradisar14 
showed that sleep disturbances preceded symptoms of 
depression among adolescents. In adults, a history of per-
sistent insomnia has been associated with a significantly 
increased risk of developing a new episode of depression 
and bipolar disorder.15 Likewise, poor objective sleep has 
predicted the recurrence of a further depressive episode,10,16,17 
and it is estimated that poor sleep precedes an episode of 
depression in 40% of cases.9 Further, there is strong evidence 
that preexisting insomnia contributes greatly to the course 
and severity of depressive disorders and even predicts relapse 
or poor outcome.18 In addition and most dramatically, poor 
sleep increases the risk of suicidal ideation19–21 and also the 
likelihood of a poorer response to combined pharmacological 
and psychological treatments of depression.17
There have typically been three options for the treat-
ment of sleep disturbances in general and in patients 
with MDD: psychopharmacotherapy,22–25 psychotherapy/
psychoeducation,26–28 and the combination of psychophar-
macotherapy and psychotherapy.29–33 Riemann and Perlis30 
have argued the need for further research on the option of 
combining psychopharmacotherapy and psychotherapy. We 
took this observation into account and compared all three 
possibilities as adjuvant treatments of MDD with a stan-
dard SSRI in a randomized three-arm study. Specifically, 
patients with MDDs and sleep disturbances were randomly 
assigned to one of the following conditions: adjuvant sleep 
hygiene program (SHP), adjuvant psychopharmacotherapy 
(lorazepam [LOR], 1 mg/d), and adjuvant sleep hygiene 
program combined with adjuvant psychopharmacotherapy 
(lorazepam [SHP-LOR], 1 mg/d). In this way, we expected 
to find some answers as regards to the treatment options for 
sleep disturbances in patients with MDD.
The following four hypotheses were formulated. First, 
following previous findings,34–37 we expected an improve-
ment in symptoms of depression over time as an effect of 
the standard treatment with an antidepressant, irrespective 
of the adjuvant treatment. Second, in light of previous 
findings,26–28 we expected a more beneficial effect of the 
adjuvant SHP on sleep, compared with the other two treat-
ment options (SHP–LOR and LOR). Third, again following 
previous findings,29–33 we expected a more beneficial effect 
of the adjuvant combined treatment (SHP–LOR) on depres-
sion, compared with the other two treatment methods (SHP 
and LOR). Fourth, on the basis of previous findings,10,38–41 
we anticipated that symptoms of depression and sleep dis-
turbances would be associated both at the beginning and at 
the end of the study.
Methods
Procedure
Eligible outpatients were approached and recruited between 
September 2013 and April 2014 at the outpatient’s center 
of the Farshchian Psychiatry Hospital of Hamedan (Iran). 
Of the 245 patients approached, 129 (52.65%) met the inclu-
sion and exclusion criteria (“Sample” section) and agreed to 
participate; 120 completed the study (statistical data analysis 
was made per protocol, and the CONSORT flow diagram 
[Figure 1] shows sampling and participants’ assignments). 
Participants were fully informed about the aims of the 
8-week study and the voluntary basis of their participation. 
Further, patients were assured of the anonymous nature of 
the data gathering. Next, they signed a written informed 
consent. Thereafter, psychopharmacological treatment of 
MDD was initiated. Two to three weeks before the study 
commenced, patients began treatment with citalopram, a 
standard SSRI, at therapeutic levels (20–40 mg/d), which 
was kept constant throughout the entire study. Psychiatrists 
and clinical psychologists not otherwise involved in the study 
performed a clinical assessment, including a diagnostic inter-
view (“Sample” section). Patients completed questionnaires 
related to sleep disturbances and to depression (“Tools” 
section) both at the beginning and at the end of the study. The 
Ethical Committee of the Hamadan University of Medical 
Sciences approved the study, which was executed accord-
ing to the ethical standards laid down in the Declaration of 
Helsinki. Further, the study was registered in Iranian Registry 
of Clinical Trials (IRCT number: 2012100411004N1).
sample
Outpatients with diagnosed MDD were enrolled in the 
study. The inclusion criteria were 1) diagnosis of MDDs 
without psychotic features, according to the Diagnostic 
and Statistical Manual of Mental Disorders, Fifth Edition; 
2) reported sleep disturbances; 3) aged between 18 years and 
65 years; and 4) willing and able to follow the study protocol 
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and to complete the questionnaires. Exclusion criteria were 
1) not meeting the inclusion criteria; 2) presence of a pro-
gressive illness (eg, cancer and dementia) directly related 
to the onset and course of insomnia; 3) use of medications 
with sleep-altering effects (eg, steroids); 4) lifetime diagnosis 
of any psychotic or bipolar disorder; 5) alcohol or drug 
abuse within the past year; 6) sleep apnea or restless legs 
(“Sleep-related assessment” section); and 7) night-shift work 
or irregular sleep pattern. All patients were treated with a 
standard SSRI, that is, with citalopram at a therapeutic level 
(20–40 mg/d).
Psychiatric assessment
Experts not further involved in the study performed the 
psychiatric assessment with the Mini International Neurop-
sychiatric Interview42 to allow selection of patients according 
to the inclusion and exclusion criteria.
sleep-related assessment
First, experts asked about current sleep quality based on 
the Insomnia Severity Index.43 Further, to exclude sleep 
disturbances due to sleep apnea and restless legs, the follow-
ing questions were asked: sleep apnea: “Are you regularly 
snoring loudly during the night?” and “Does your partner 
[or somebody else] tell you that you stop breathing during 
the night?”; restless legs syndrome: “Do you feel discomfort 
in your legs in the evening such as an itch you can’t scratch, 
a ‘buzzing sensation’, an unpleasant ‘tickle that won’t stop’, 
a ‘crawling’?” and “Do feelings of discomfort disappear 
when you start moving your legs?”. Answering “yes” to 
one of the abovementioned questions led to exclusion from 
the study.
randomization and intervention groups
A psychologist not further involved in the study prepared a 
total of 129 raffle tickets, 43 in each of three different colors, 
put them in a ballot box and stirred. At the start of the study, 
patients drew a raffle ticket and were assigned the group with 
the defined color.
The following groups and interventions were defined: 
1) SHP (n=43), 2) tablet 1 mg of LOR nightly (n=43), and 
3) SHP–LOR nightly (n=43).
interventions
sleep hygiene program
In addition to the standard treatment with citalopram, 
patients received four sessions (30–45 minutes; group or 
individual sessions) of a SHP, based on Silberman’s Insom-
nia workbook.44 Psychologists not further involved in the 
study delivered these sessions. The first session took place 
at the beginning of the study, and the last session 2 weeks 
before the end of the study. Specifically, participants learned 
$VVHVVHGIRUHOLJLELOLW\Q 
([FOXGHGQ Ƈ1RWPHHWLQJLQFOXVLRQFULWHULDQ Ƈ'HFOLQHGWRSDUWLFLSDWHQ 
$QDO\]HGQ 
'LVFRQWLQXHGLQWHUYHQWLRQQ 
$OORFDWHGWRLQWHUYHQWLRQ6+3Q Ƈ5HFHLYHGDOORFDWHGLQWHUYHQWLRQQ 
'LVFRQWLQXHGLQWHUYHQWLRQQ 
$OORFDWHGWRLQWHUYHQWLRQ6+3/25Q Ƈ5HFHLYHGDOORFDWHGLQWHUYHQWLRQQ 
$OORFDWLRQ
$QDO\VLV
)ROORZXS
5DQGRPL]HGQ 
(QUROOPHQW
$OORFDWHGWRLQWHUYHQWLRQ/25Q Ƈ5HFHLYHGDOORFDWHGLQWHUYHQWLRQQ Ƈ'LGQRWUHFHLYHDOORFDWHGLQWHUYHQWLRQQ 
$QDO\]HGQ  $QDO\]HGQ 
'LVFRQWLQXHGLQWHUYHQWLRQQ 
Figure 1 CONSORT 2010 flow diagram.
Abbreviations: shP, sleep hygiene program; shP-lOr, sleep hygiene program + lorazepam (1mg/d); lOr, lorazepam (1mg/d).
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about basics of sleep hygiene such as keeping a regular 
sleep–wake schedule; avoiding abundant, late, and fatty 
dinners, but eating small, light, and easily digested meals 
to avoid being hungry during the night; moving a lot during 
the day and even in the evening;45 avoiding naps; keeping 
a sleep and activity log for seven consecutive days; avoid-
ing stimulants in the evening (coffee, tea, coke, high sugar 
soft drinks, alcohol, drugs, and nicotine); going to bed later 
and getting up early to increase sleep need; and using the 
bedroom exclusively for romance and sleep (thus, avoiding 
screen time and eating in the bed room/bed). Further, during 
the sessions, participants were instructed in relaxation tech-
niques to improve their ability to relax body and mind in 
the evening and so fall asleep more easily. During the four 
sessions, these techniques were practiced. Finally, patients 
also received a leaflet comprising information regarding 
sleep hygiene, the importance of sleep, and sleep hygiene 
practices. It contained representative information regarding 
adult’s sleep and healthy sleep practices in general, as well as 
recommendations about sleep duration for adults, recommen-
dations about the temporal organization of sleep, information 
about different behaviors and environmental factors that can 
influence sleep quality, and about the importance of sleep 
and consequences of sleepiness. The leaflet also contained 
an example of a sleep–wake diary and an explanation for its 
use. It was designed by professional graphic designers on a 
single unfolded sheet of paper, printed on both sides. The 
dimensions of the leaflet were 21×21 cm2.
Pharmacotherapy
In addition to the standard treatment with citalopram, patients 
in the pharmacotherapy group were treated for 8 weeks with 
LOR. LOR is a benzodiazepine. Although the manufacturer 
advises discontinuing regular LOR intake after 3–4 weeks, 
the US Federal Drug and Food Administration has approved 
all hypnotics since 2005 without restriction as to duration 
of use.23 The focus of the four pharmacotherapy sessions 
(30–45 minutes) was on medication management; this 
involved education about medications, adjustment of dosage 
and dosage schedules, and discussions of adverse effects. All 
patients in the pharmacotherapy conditions began treatment 
with LOR at 1 mg/d.
combined sleep hygiene program and 
pharmacotherapy
In addition to the standard treatment with citalopram, 
patients assigned to this study condition had four sessions 
(45–50 minutes) each on sleep hygiene and on medication 
management, as described in the “Sleep hygiene program” 
and “Pharmacotherapy” sections. Thus, participants in this 
treatment condition received both the SHP and the medica-
tion (LOR).
Tools
assessment of sleep patterns and quality (self-rating)
To assess sleep patterns and quality, the Persian46 version 
of Pittsburgh Sleep Quality Index (PSQI)47 was employed. 
The PSQI is a self-report questionnaire that assesses sleep 
quality over a 1-month interval. It consists of 19 individual 
items generating seven “component” scores: subjective sleep 
quality, sleep latency (ie, how long it takes to fall asleep), 
sleep duration, habitual sleep efficiency (ie, the percentage 
of time in bed that one is asleep), sleep disturbances, use of 
sleep medication, and daytime dysfunction. Nazifi et al46 have 
reported appropriate internal consistency (Cronbach’s alpha 
of 0.85) for its clinically calculated seven components.48,49 
Nazifi et al’s findings are consistent with those for the English 
version of the PSQI.47–49 Scores are combined according to the 
scoring criteria included with the form to produce a Global 
PSQI Score. Scores above 5 indicate clinically relevant levels 
of disturbed sleep.
assessment of symptoms of depression (self-rating)
The Persian version of Beck Depression Inventory (BDI50) 
was used to measure depressive symptoms.51 The BDI 
samples self-reported symptoms of depression. The ques-
tionnaire consists of 21 items and asks about different 
dimensions such as depressive mood, loss of appetite, sleep 
disorders, suicidality, and similar issues. Each question has 
a set of at least four possible responses reflecting a range of 
intensity; for example, “sadness”: 0= “I do not feel sad”; 
1= “I feel sad”; 2= “I am sad all the time and I can’t snap 
out of it”; 3= “I am so sad or unhappy that I can’t stand it”. 
Higher scores reflect greater severity of depressive symptoms 
(Cronbach’s alpha =0.88).
statistical analysis
Of the 129 patients initially enrolled, all but nine completed 
the study. The statistical analysis was performed as per 
protocol.
A series of chi-squared tests were computed to check 
for possible sociodemographic (sex, socioeconomic status, 
civil status, and job position) differences between the three 
groups. A one-way analysis of variance was calculated to 
check for possible age differences. To test whether symptoms 
of depression and sleep quality differed over time or between 
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groups, two analyses of variance for repeated measures were 
performed with the factors time (pre vs post), group (SHP, 
LOR, and LOR–SHP), and time by group interaction, and as 
dependent variables symptoms of depression and sleep qual-
ity. Post-hoc tests were performed with Bonferroni–Holm cor-
rections for P-values. Effect sizes were reported as partial eta 
squared (η2
p
), and the nominal level of significance was set at 
α#0.05. All statistics was performed with SPSS® 23.0 (IBM 
Corporation, Armonk, NY, USA) for Apple Mac®.
Results
Psychosocial dimensions of the sample
Table 1 reports the descriptive and inferential statistics of 
the sample, separately by the interventions (SHP, LOR, and 
SHP–LOR).
The three groups did not differ in age, sex distribution, 
socioeconomic status, civil status, or job position. Accord-
ingly, these dimensions were not introduced as possible 
confounders.
sleep disturbances
Table 2 gives all statistical indices (descriptive and inferen-
tial statistics); therefore, statistical indices are not repeated 
in the text.
As shown in Table 2 and Figure 2, sleep disturbances 
decreased significantly over time. Neither group differences 
nor the time by group interaction was significant.
Depression scores
As shown in Table 2 and Figure 3, symptoms of depression 
decreased significantly over time. Compared with SHP and 
LOR–SHP groups, the LOR group had higher depression 
scores. The significant time by group interaction showed 
that symptoms of depression decreased significantly more 
over time in the SHP and SHP–LOR groups than in the 
LOR group.
correlations between symptoms of 
depression and sleep disturbances at the 
beginning and at the end of the study
Table 3 gives an overview of the correlations between symp-
toms of depression and sleep disturbances at the beginning 
and at the end of the study. While symptoms of depression 
at the beginning and at the end of the study did significantly 
correlate, no significant or meaningful correlations were 
found for sleep disturbances.
Discussion
The key findings of this first randomized study of three 
different adjuvant treatment methods to improve sleep and 
depression among a sample of outpatients with MDD were 
as follows. All three methods (SHP, LOR, and SHP–LOR) 
improved sleep, with no advantages for any one method. 
They improved symptoms of depression, with advantages 
for the SHP and SHP–LOR conditions; more specifically, the 
combination (SHP–LOR) reduced symptoms of depression 
most effectively, a finding, which expands upon the current 
literature in an important way. Four hypotheses were formu-
lated, and each of these is considered in turn.
Our first hypothesis was that symptoms of depression 
would reduce over time, and this was fully confirmed. There-
fore, the present results confirm the wealth of studies34–37 
showing a favorable effect of antidepressants on both symp-
toms of depression and sleep.
Our second hypothesis was that the adjuvant combined 
treatment (SHP–LOR) would have a more beneficial effect 
on sleep than the other two treatment methods (SHP and 
LOR), but this was not confirmed; all three interventions had 
comparable effects. Therefore, the pattern of results is at odds 
with previous research.26–28 The pattern of results suggests 
that treatment with adjuvant LOR and with adjuvant psycho-
education had similarly beneficial effects on sleep. However, 
given the possible risk of benzodiazepine dependence,52,53 
Table 1 Descriptive and inferential statistics of sociodemographic variables, separately for the three study conditions (shP, lOr, and 
shP–lOr)
Sociodemographic variables Groups Statistics
SHP LOR SHP–LOR
n 40 40 40
sex (f/m) 23/17 21/19 34/16 χ2(N=120, df=2) =0.48, P.0.1
age (years) 46.88 (8.60) 49.23 (7.92) 48.65 (8.73) F(2, 117) =1.43, P.0.1
socioeconomic status (low/middle/high) 26/14/0 33/7/0 27/13/0 χ2(N=120, df=2) =3.53, P.0.1
civil status (single/married/single-separated) 2/36/2 4/35/1 5/31/4 χ2(N=120, df=4) =3.68, P.0.1
Job position (employed/housework/unemployed) 27/5/8 24/3/13 23/7/10 χ2(N=120, df=4) =3.18, P.0.1
Abbreviations: shP, sleep hygiene program; lOr, lorazepam; f/m, female/male; shP–lOr, sleep hygiene program combined with lorazepam.
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clinicians should balance the risks and benefits of LOR or 
benzodiazepine prescription against psychoeducational inter-
ventions; these latter in the short term need more engagement 
to acquire the necessary skills but in the long run have no 
side effects and improve patients’ self-efficacy.
To explain why psychoeducational interventions may 
work, theoretical models suggest that knowledge alone is 
rarely sufficient to achieve behavioral change. Rather, accord-
ing to social cognitive models such as the theory of planned 
behavior, behavior is influenced by intentions and perceived 
control of behavior and the importance accorded to the inter-
vention by significant others. To put it another way, the deter-
mining factors are whether the recipients of sleep education 
perceive the behavior to be desirable, positive, or worthwhile 
and the degree to which others, such as relatives, friends, or 
colleagues, approve of healthy sleep behavior.54–56
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Our third hypothesis was that the adjuvant combined 
treatment (SHP–LOR) would have a more beneficial effect 
on depression than the other two treatment methods (SHP and 
LOR), and this was confirmed; this combination of treatments 
led to a greater reduction in symptoms of depression, though 
the SHP alone also produced greater improvement than the 
intervention with LOR which had the smallest impact. These 
findings, therefore, accord with previous research.31,32,57,58 
In light of these findings, and if we again consider the 
potential risk of benzodiazepine dependence,52,53 clinicians 
should balance the risks and benefits of LOR or benzodiaz-
epine prescription. This caution is particularly relevant given 
that psychotherapeutic and psychoeducational programs usu-
ally have a long-lasting effect for a broad variety of mental 
illnesses,59 depression,60–63 and sleep problems.64–68
Our fourth hypothesis was that symptoms of depression 
and sleep disturbances would be associated both at the begin-
ning and at the end of the study, but the results did not support 
this. Rather, the results pattern suggests that symptoms of 
depression and sleep disturbances were not connected. This 
finding demands particular attention given that symptoms 
of depression and sleep disturbances are usually highly 
intertwined.10,38–40 Specifically, Fava41 reported that insomnia 
and daytime sleepiness were often associated with depres-
sion. Strikingly, Lovato and Gradisar14 showed in their meta-
analysis that, among adolescents, sleep disturbances preceded 
symptoms of depression and not vice versa. The evidence 
available from the present study cannot shed any light on the 
underlying psychological and physiological mechanisms. 
However, we offer the following speculative interpretations. 
First, it is conceivable that the tool (PSQI47) was too coarse 
grained to detect subtle changes in sleep. Responses restricted 
to a four-point Likert scale might be too insensitive to register 
changes. On the other hand, the PSQI is an internationally 
well-regarded and validated instrument in sleep research. 
Second, floor effects are possible given that one item asks for 
intake of sleep medication, and patients were bound to score 
high because they were under antidepressant treatment and 
in case of the LOR group, under additional benzodiazepine. 
Third, there was really no higher improvement.
The novelty of the findings should be balanced against 
the following limitations. First, participants were not blind 
as to treatment, and therefore, it is conceivable that expec-
tancies and motivational processes might have biased the 
results. Second, it is also conceivable that further latent but 
unassessed psychophysiological factors might have biased 
two or more variables in the same or opposite direction. 
Third, evidence at the neuronal and endocrinological levels 
such as cortisol, growth hormone, alpha-amylase, or BDNF 
could have shed more light on the neurophysiological 
processes underlying the positive changes in symptoms of 
depression and sleep disturbances. Fourth, objective sleep 
measurements (actigraphy and sleep-EEG) would have been 
helpful in estimating objective changes in sleep. However, 
for larger samples such as the present one, questionnaires 
are still the gold standard.69 Fifth, we relied on self-ratings. 
Future studies might also collect experts’ ratings as regards 
patients’ symptoms of depression. Specifically, experts 
could have rated patients’ symptoms of depression with the 
Montgomery–Asberg Depression Rating Scale, which con-
sists of ten items and has been recently validated.70 Sixth, we 
assessed neither the intensity nor the quality of the patient–
therapist time. Though patients in the LOR condition had four 
pharmacotherapy sessions, it is conceivable that patients in 
the sleep hygiene psychoeducation had further benefits from 
the psychotherapeutic setting. Seventh, we performed a per 
protocol analysis, whereas an intention-to-treat approach 
would have been more correct; however, comparing the 
pattern of results of the two statistical approaches, no descrip-
tive or significant differences were observed. Last, it would 
have been very useful and important to follow up these 
patients, as there is some, but as yet insufficient, evidence 
that psychotherapeutic interventions have a long-lasting 
effect than psychopharmacotherapy.29
Conclusion
The findings of this study indicate that an adjuvant SHP and 
its combination with LOR can produce greater improvements 
in symptoms of depression. As regards to sleep disturbances, 
no intervention (SHP, LOR, and SHP–LOR) showed superior 
effects. Therefore, in light of the increased risk of benzodi-
azepine dependence, clinicians should carefully balance the 
risks and benefits in prescribing LOR as an add-on to treat 
both depressive disorders and sleep disturbances.
Table 3 Overview of the correlations (Pearson’s r) between 
symptoms of depression and sleep disturbances at the beginning 
and at the end of the study
BDI and 
PSQI
Groups
1, r 2, r 3, r 4, r
1 BDi pre – 0.25* -0.04 0.17
2 BDi post – -0.06 0.07
3 PsQi pre – -0.03
4 PsQi post –
Note: *P,0.05.
Abbreviations: BDi, Beck Depression inventory; PsQi, Pittsburgh sleep Quality 
index.
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